Bibliography
- Sainsbury R. Ovarian ablation in the adjuvant treatment of premenopausal and perimenopausal breast cancer. Br J Surgery 2003;90:517-26
- Cheer SM, Plosker GL, Simpson D, Wagstaff AJ. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. Drugs 2005;65(18):2639-55
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
- LHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369(9574):1711-23
- Baum M, Hackshaw A, Houghton J, ; ZIPP International Collaborators Group. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer 2006;42(7):895-904
- Hackshaw A, Baum M, Fornander T, Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 2009;101(5):341-9
- Kaufmann M, Jonat W, Blamey R, ; Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group. Survival analyses from the ZEBRA study: goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003;39(12):1711-7
- Castiglione-Gertsch M, O'Neill A, Price KN, ; International Breast Cancer Study Group (IBCSG). Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003;95(24):1833-46
- Bernhard J, Zahrieh D, Castiglione-Gertsch M, ; International Breast Cancer Study Group Trial VIII. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients–the International Breast Cancer Study Group Trial VIII. J Clin Oncol 2007;25(3):263-70
- Davidson NE, O'Neill AM, Vukov AM, Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005;23(25):5973-82
- Mitsuyama S, Nomura Y, Ohno S, Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B. Gan To Kagaku Ryoho 2005;32(13):2071-7
- Klijn JG, Blamey RW, Boccardo F, Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2001;19(2):343-53
- Fogelman I, Blake GM, Palmer M, Bone mineral density in premenopausal women treated for node-negative early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003;14:1001-6
- Sverrisdottir A, Fornander T, Jacobsson H, Bone mineral density among premenopausal women with early breast cancer in a randomised trial of adjuvant endocrine therapy. J Clin Oncol 2004;22:3694-9
- Gnant MFX, Mlineritsch B, Luschin-Ebengreuth G, Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25(7):820-8
- Brufsky A, Bundred N, Coleman R, ; for the Z-FAST and ZO-FAST Study Groups. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008;13:503-14
- Gnant M, Mlineritsch B, Schippinger W, ; ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360(7):679-91
- Blamey RW. Guidelines on endocrine therapy of breast cancer: EUSOMA. Eur J Cancer 2002;38:615-34
- Harbeck N, Jakesz R. St Gallen 2007: Breast cancer treatment consensus report. Breast Care 2007;2:130-4
- Rabaglio M, Aebi S, Castiglione-Gertsch M. Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncol 2007;8(10):940-9
- Available from: http://clinicaltrials.gov/ct2/show/NCT00322348
- Jonat W, Pritchard KI, Sainsbury R, Klijn JG. Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient. J Cancer Res Clin Oncol 2006;132(5):275-86
- Regan MM, Pagani O, Walley B, ; SOFT/TEXT/PERCHE Steering Committee; International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 2008;19(7):1231-41